tion (ICD-10) (6) . The survival analysis used 1,151,789 cancer cases first diagnosed during 1993-2005 from the KNCI DB, and followed vital status through 31 December 2006.
Mortality data from 1983 to 2005 were obtained from the Korea National Statistics Office (KNSO) (1). Cause of death was coded and classified according to the ICD-10. The population data were also obtained from KNSO using the resident registration population on 1 July.
Analysis
Crude rates (CRs) and age-specific rates of cancer incidence and mortality were calculated. Age-standardized rates (ASRs) were determined using the World Health Organization (WHO) world standard population (7) . The cumulative risks of cancer incidence, which are the probability of developing cancer to the life expectancy, were also calculated. Changes in the annual age-standardized cancer incidence rates were examined by calculating the annual percentage change (APC) over a time period as 100(e-1), where e is the slope of the regression of log age-standardized rates on a calendar year (8) .
The survival duration of each case was determined as the time difference between the date of initial diagnosis and the date of death, date of loss to follow-up, or closing date for follow-up. Observed survival rates were calculated using a life table method and relative survival rates were examined with the Ederer II method (9) using an algorithm written in SAS by Paul Dickman (10) , with some minor adaptations.
SELECTED FINDINGS
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Trends in cancer incidence
Tables 5.1-5.3 show the trends in cancer incidence for all sites combined and for selected cancer sites. The incidence rate for all sites combined increased by 2.5% annually from 1999 to 2005. The incidence rate for all sites combined increased by 1.2% annually in men and by 4.1% in women from 1999 to 2005.
The incidence rates have continued to increase for colorectal and thyroid cancer in both sexes, along with breast cancer in females and prostate cancer in males. Stomach and lung cancer incidence rates plateaued in men and women, while the incidences of liver cancer in both sexes and the cervix in women have decreased.
One notable aspect is the sharp increase (25.1% annually) in the incidence of female thyroid cancer. As diagnostic techniques for thyroid cancer have become more sensitive, such as with the advent of ultrasound and fine-needle aspiration, the detection of subclinical disease has become possible. Therefore, the increased incidence of thyroid cancer might reflect improved diagnostic techniques for previously undetected disease, rather than a true increase in the occurrence of thyroid cancer (11, 12) . 
Trends in cancer mortality
Figs. 1&2 show the trends in cancer deaths for all sites combined and for selected cancer sites. Age-standardized mortality rates have decreased for all sites combined in both sexes since 2002.
For lung cancer, the leading site for cancer deaths since 1999, mortality has decreased slightly for men since 2001, but increased significantly in women. The age-standardized mortality rates of stomach and cervix uteri cancer have decreased continuously. Along with the significant increases in colorectal, prostate and female breast cancer incidence, the mortality rates of these cancers have also continued to increase. Age-specific incidence rates for selected cancer sites Table 6 presents the most common cancer sites by sex and age group. For ages 0-14 yr, leukemia was the most common form in both sexes. For males, stomach cancer was the most common in 15-64-yr-olds, while lung cancer was more frequent for those 65 and over. For females, the most common sites of cancer were the thyroid, breast and stomach for the 15-34-yr-old, 35-64-yr-old, and the 65 and over age groups, respectively. Fig. 3 shows the age-specific incidence rates of the selected cancers for men and women. The data show that the incidence of stomach, lung, liver and colorectal cancers increased gradually with age. In women, the age-specific incidence rates of breast and thyroid cancer has increased with age until the forties and decreased thereafter. Table 7 shows the 5-yr relative survivals for three periods: 1993-1995, 1996-2000, and 2001-2005 . Notable improvement has been made in the 5-yr relative survival rates for all sites combined. The survival of females appears to have a better prognosis than that of males. This is partly explained by the high frequency of female cancers (e.g., thyroid, breast and uterine cervix) known to have relatively good prognoses.
Survival rates
The 5-yr relative survival rates appeared to be higher for most major cancer sites in patients diagnosed during 2001-2005 compared to 1993-1995, except for cancers of the pancreas, brain and central nervous system. The greatest improvements were seen in leukemia, non-Hodgkin's lymphoma, 
